Abbott has agreed to pay Reata Pharmaceuticals US$400 M upfront in order to gain a global licence to co-develop and co-commercialise the biotech’s preclinical, second-generation antioxidant inflammation modulators (AIM). The deal will cover a broad range of molecules across a number of therapeutic areas. The two companies will equally share costs and profits for new AIMs in newly licensed indications, except for rheumatoid arthritis and other select autoimmune diseases for which Abbott will assume 70% of the costs and receive 70% of the profits.